AMAG Pharmaceuticals upgraded to Outperform from Market Perform at Leerink Leerink upgraded AMAG Pharmaceuticals on expectations Feraheme sales estimates are now achievable and label expansion can drive upside. The firm raised its price target for shares to $19 from $17.
AMAG Pharmaceuticals transferred with a Market Perform at FBR Capital FBR Capital transferred coverage of AMAG Pharmaceuticals with a Market Perform rating, a downgrade from its previous rating of Outperform. FBR believes Feraheme growth will be limited to market share gains and that Makena expectations are fully realized at current valuation levels. The firm has a $42 price target for AMAG shares.